Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine - RenovoRx

Next Previous
Drug Profile

Gemcitabine - RenovoRx

Alternative Names: Gemcitabine + RenovoCath - RenovoRx; gemcitabine intra-arterial infusion via the RenovoCath™ RC120 catheter; IAG - RenovoRx; Intra-arterial gemcitabine; RenovoGem™

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RenovoRx
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Cholangiocarcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer

Most Recent Events

  • 07 Aug 2026 RenovoRx completes enrolment in the phase III TIGeR-PaC trial for Pancreatic cancer (Late stage disease, Inoperable/Unresectable) in USA (Intra-arterial) (NCT03257033)
  • 26 May 2026 Pharmacokinetics and pharmadynamics data from a phase-III TIGeR-PaC trial in Pancreatic cancer released by RenovoRx
  • 06 May 2025 RenovoRx has patent protection for methods for treating tumors in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top